Heparin-induced thrombocytopenia (HIT) is caused by platelet-activating IgG antibodies that recognize platelet factor 4 (PF4) bound to heparin. Immunogenicity of heparins differs in that unfractionated heparin (UFH) induces more anti-PF4/heparin antibodies than low-molecular-weight heparin (LMWH) and UFH also causes more HIT. Fondaparinux, a synthetic anticoagulant modeled after the antithrombi...

2112. 13. Lassen, M. R. (2000) The EPHESUS study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH). The prevention of venous thromboembolism (VTE) after elective hip replacement surgery. Blood 96(11), Abstract #2109. 14. Erickson, B. (2000) The PENTHIFRA study: comparison of the first synthetic Factor Xa inhibitor with low molecular weight heparin (...

A novel thiol fluorophore was synthesized to be selectively attached to the non-reducing end of low molecular weight heparin (LMWH) via a Michael addition. Double labeling of LMWH was demonstrated to be a feasible approach for the determination of heparinase II activity by FRET.

Fondaparinux, a subcutaneous synthetic pentasaccharide that selectively inhibit factor Xa, seems to be a safe and efficacious alternative to low molecular weight heparin in prevention and treatment of venous thromboembolism in pregnant women who had developed severe adverse reactions to heparin. Two women with previous cerebral vein thrombosis received antithrombotic prophylaxis during pregnanc...

Thromboelastography (TEG) has been used increasingly as an intraoperative hemostasis monitoring device. Low-molecular-weight heparins are given increasingly to reduce the development of antibodies against the heparin–platelet factor 4 complex, and heparinoids are given to patients who have developed the antibody. We studied the effect of unfractionated heparin, a low-molecular-weight heparin (e...

The issue of how and when to monitor low-molecular-weight heparin (LMWH) therapy was raised from the beginning of the clinical use of these compounds, almost 20 years ago. Laboratory monitoring of LMWHwas suggested mainly because the new compounds were to replace unfractionated heparin (UFH), which definitely required monitoring. In the following, we will briefly review the reasons for monitori...

BACKGROUND Heparin is a potential anti-inflammatory drug for allergic airway inflammation. To elucidate the effects of heparin on allergic inflammation, we examined the in vivo effects of heparin on antigen-induced mucus hypersecretion and infiltration of eosinophils and neutrophils in the nasal epithelium of sensitized rats. METHODS We induced hypertrophic and metaplastic changes of goblet c...

BACKGROUND Body weight-adjusted subcutaneous low-molecular-weight heparin (LMWH) has been proven to be at least as effective and safe as dose-adjusted intravenous unfractionated heparin (UFH) for the treatment of patients with venous thromboembolism. However, body weight-adjusted dosage of low-molecular-weight heparin may be cumbersome and could lead possibly to incorrect dosing. Therefore a fi...

INTRODUCTION Thromboelastography (TEG) is a technique that measures coagulation processes and surveys the properties of a viscoelastic blood clot, from its formation to lysis. AIM To determine the possible hypercoagulability state and the effect of antithrombotic prophylaxis on thromboelastogram results and development of venous thrombosis during laparoscopic fundoplication. MATERIAL AND ME...

Heparin is one of the oldest biological medicines, and has an established place in the prevention and treatment of venous thrombosis. Low-molecular-weight heparins (LMWH) have been developed by several manufacturers and have advantages in terms of pharmacokinetics and convenience of administration. They have been shown to be at least as effective and safe as unfractionated heparin and have repl...